Skip to main content
. Author manuscript; available in PMC: 2010 Sep 30.
Published in final edited form as: J Neurosci. 2010 Mar 31;30(13):4757–4766. doi: 10.1523/JNEUROSCI.6108-09.2010

Figure 5. FRAP of GFP-SAP102 and GFP-PSD-95 in the presence of the actin stabilizer Jasplakinolide.

Figure 5

A–C. The images represent FRAP of neurons expressing GFP-actin (A), GFP-SAP102 (B) and GFP-PSD-95 (C) in the presence of Jasplakinolide. The fluorescence of the same areas before (Pre) and at 0 and 120 (or 300) seconds after photobleaching are shown. Scale bar, 1 μm. D. FRAP sample of transfected GFP-actin in spines. The recovery was totally blocked by incubating the neurons with actin stabilizer Jasplakinolide (10 μM) for 30 minutes before FRAP measurement. The solution also contained 10 μM Jasplakinolide during imaging. Untreated cultures (black) and Jasplakinolide treated cultures (gray) are shown over a 120-second recording. Jas = Jasplakinolide. E. FRAP of GFP-SAP102 was partly blocked by pretreatment of Jasplakinolide for 30 minutes. N = 5 for DMSO control and n = 7 for Jasplakinolide treatment. F. FRAP of GFP-PSD-95 was not affected by pretreatment of Jasplakinolide. N = 8 for each. G. The immobile fraction of GFP-SAP102 increased and the slow mobile fractions decreased after Jasplakinolide treatment. There was no significant change for rapid mobile fractions after Jasplakinolide treatment. *p<0.05, Ctrl = control. H. There was no significant change for the immobile, slow mobile and rapid mobile fractions of GFP-PSD-95 after stabilizing actin with Jasplakinolide.